StreetInsider.com News Articles

Form 6-K InflaRx N.V. For: Oct 22

Thu, 22 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261022/27222628.html

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

Thu, 22 Oct 2026 12:00:00 -0400

Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection
Structural modeling provides new insight into izicopan’s differentiated molecular profile

Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

Thu, 22 Oct 2026 12:00:00 -0400

Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection
Structural modeling provides new insight into izicopan’s differentiated molecular profile

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

Fri, 02 Oct 2026 07:30:00 -0400

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.

Kidney Week 2026 Late-Breaking Poster Details

Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models.

Poster Session
Session Title: Late-Breaking Research Posters [LB-PO]
Session Date, Time: October 22, 2026

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

Fri, 02 Oct 2026 07:30:00 -0400

Kidney Week 2026 Late-Breaking Poster Details

Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models.

Poster Session
Session Title: Late-Breaking Research Posters [LB-PO]
Session Date, Time: October 22, 2026

InflaRx names Gabriela Alperovich as clinical development head

Thu, 01 Oct 2026 07:31:05 -0400

InflaRx N.V. (Nasdaq: IFRX) announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President and Global Head of Clinical Development, effective October 1, 2026.

Dr. Alperovich joins InflaRx from CSL Vifor, where she most recently served as Executive Director, Global Clinical Lead for Cardiovascular and Renal. Over more than 20 years in the pharmaceutical industry, she has held clinical development and medical affairs leadership roles at CSL Vifor, AbbVie, and Bristol-Myers Squibb. Her experience includes leading Phase 2 and Phase 3 registrational programs across indications such as IgA nephropathy, focal segmental glomerulosclerosis, and kidney transplant, with regulatory submissions and

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Thu, 01 Oct 2026 07:30:00 -0400

Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026.

Dr. Alperovich is a physician-scientist and nephrologist with more than two decades of experience in the global pharmaceutical industry, spanning senior leadership roles across clinical development and medical affairs, and a track record of advancing Phase 2 and registrational programs in immune-inflammatory renal diseases through to regulatory submission

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Thu, 01 Oct 2026 07:30:00 -0400

InflaRx to Host Virtual Capital Markets Day

Mon, 21 Sep 2026 07:30:00 -0400

Event to be hosted on November 3, 2026 at 8:00 AM EST
Featured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl

Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST / 2:00 PM CET to approximately 9:00 AM EST / 3:00 PM CET. The timing of the event has been shifted to

InflaRx to Host Virtual Capital Markets Day

Mon, 21 Sep 2026 07:30:00 -0400

Event to be hosted on November 3, 2026 at 8:00 AM EST
Featured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl

Needham Starts Inflarx NV (IFRX) at Buy

Mon, 14 Sep 2026 06:24:02 -0400

Needham analyst Joseph Stringer initiates coverage on Inflarx NV (NASDAQ: IFRX) with a Buy rating and a price target of $8.00.

For an analyst ratings summary and ratings history on Inflarx NV click here. For more ratings news on Inflarx NV click here.

Shares of Inflarx NV closed at $2.09 yesterday.

Needham Starts Inflarx NV (IFRX) at Buy

Mon, 14 Sep 2026 06:24:02 -0400

Needham analyst Joseph Stringer initiates coverage on Inflarx NV (NASDAQ: IFRX) with a Buy rating and a price target of $8.00.

For an analyst ratings summary and ratings history on Inflarx NV click here. For more ratings news on Inflarx NV click here.

Shares of Inflarx NV closed at $2.09 yesterday.

InflaRx Announces Participation in September Investor Conferences

Thu, 20 Aug 2026 07:30:00 -0400

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows: